RecruitingCentral Line Associated Blood Stream Infections (CLABSI)
Comparing The Safety And Efficacy Of DEFENCATH® In Reducing Central-Line Bloodstream Infections (CLABSIs) In Adults And Adolescent Participants Receiving Total Parenteral Nutrition Through A Central Venous Catheter (CVC)
Eligible age
12+ yrs
Accepts
All genders
Locations
16 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This is a Phase 3, randomized, double-blind, controlled, adaptive, 2-arm, multicenter study to demonstrate the efficacy and safety of DefenCath in adult and adolescent participants receiving home Total Parenteral Nutrition (TPN) via Central Venous Catheter (CVC) compared with heparin.
Sponsor: CorMedix Therapeutics
You may not qualify if…
- ✕ 1. Any participant unable or not willing to sign inform consent or, in the case of adolescents, not willing to provide assent.
- ✕ 2. Any participant who is currently receiving systemic antibiotics. Topical antibiotics are permitted. Use of metronidazole or rifaximin for treating small intestinal bacterial overgrowth (SIBO) is also permitted.
- ✕ 3. Any participant with visible evidence of compromised skin integrity present at the catheter exist site or catheter exit site infection.
- ✕ 4. Any participant with a secondary CVC in addition to the primary TPN line.
- ✕ 5. Any participant that has received thrombolytic treatment (e.g., tissue-type plasminogen activator \[tPA\]-Cathflo), not as a part of the institution's standard of care for patency management, in current catheter within 30 days of randomization.
- ✕ 6. Any participant with unstable arrhythmia, defined as presence of hemodynamic instability within a month prior to the baseline assessment.
- ✕ 7. Any participant using any type of antimicrobial-coated or heparin-coated catheter.
- ✕ 8. Any participant with documented chronic bleeding diathesis, active or recurrent bleeding within 1 month prior to randomization.
Where it's recruiting
California
Los Angeles
District of Columbia
Washington D.C.
Florida
Doral
Georgia
Atlanta
Illinois
Chicago · Maywood
Iowa
Iowa City
Maryland
Baltimore
Minnesota
Rochester
Nebraska
Omaha
New York
New York
North Carolina
Durham
Ohio
Cleveland
Source: ClinicalTrials.gov · NCT06822426 · last updated 2026-09-25